[Federal Register Volume 75, Number 45 (Tuesday, March 9, 2010)]
[Notices]
[Pages 10789-10790]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4954]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Meeting of the Uniform Formulary Beneficiary Advisory Panel

AGENCY: Assistant Secretary of Defense (Health Affairs), DoD.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: Under the provisions of the Federal Advisory Committee Act of 
1972 (5 U.S.C., Appendix) and the Government in the Sunshine Act of 
1976 (5 U.S.C. 552b) the Department of Defense announces that the 
Uniform Formulary Beneficiary Advisory Panel (hereafter referred to as 
the Panel) will meet on March 25, 2010.

DATES: The meeting will be held on March 25, 2010, from 8 a.m. to 5 p.m 
and will be open to the public from 9 a.m. to 5 p.m.

ADDRESSES: The meeting will be held at the Naval Heritage Center 
Theater, 701 Pennsylvania Avenue, NW., Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: Lieutenant Colonel Thomas Bacon, 
Designated Federal Officer, Uniform Formulary Beneficiary Advisory 
Panel, 5111 Leesburg Pike, Skyline 5, Suite 810, Falls Church, VA 
22041-3206, Telephone: (703) 681-2890 Fax: (703) 681-1940, E-mail: 
<a href="/cdn-cgi/l/email-protection#5c1e3d2c2e392d29392f282f1c28313d72332f3872313530"><span class="__cf_email__" data-cfemail="bcfeddccced9cdc9d9cfc8cffcc8d1dd92d3cfd892d1d5d0">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION:

Purpose of Meeting

    The Panel will review and comment on recommendations made to the 
Director, TRICARE Management Activity, by the Pharmacy and Therapeutics 
Committee regarding the Uniform Formulary.

Meeting Agenda

    Sign-In; Welcome and Opening Remarks; Public Citizen Comments; 
Scheduled Therapeutic Class Reviews--Basal Insulins; Antihemophilic 
Factors; Designated Newly Approved Drugs and Drugs recommended for non-
formulary placement due to non-compliance with Fiscal Year 2008, 
National Defense Authorization Act, Section 703; Panel Discussions and 
Vote, and comments following each therapeutic class review.

Meeting Accessibility

    Pursuant to 5 U.S.C. 552b, as amended, and 41 CFR 102-3.140 through 
102-3.165, and the availability of space this meeting is open to the 
public from 9 a.m. to 5 p.m. Seating is limited and will be provided 
only to the first 220 people signing in. All persons must sign in 
legibly.

Administrative Work Meeting

    Prior to the public meeting the Panel will conduct an 
Administrative Work Meeting from 8 a.m. to 9 a.m. to discuss 
administrative matters of the Panel. The Administrative Work Meeting 
will be held at the Naval Heritage Center, 701 Pennsylvania Avenue, 
NW., Washington, DC, 20004. Pursuant to 41 CFR 102-3.160, the 
Administrative Work Meeting will be closed to the public.

Written Statements

    Pursuant to 41 CFR 102-3.105(j) and 102-3.140, the public or 
interested organizations may submit written statements to the 
membership of the Panel at any time or in response to the stated agenda 
of a planned meeting. Written statements should be submitted to the 
Panel's Designated Federal Officer. The Designated Federal Officer's 
contact information can be obtained from the General Services 
Administration's Federal Advisory Committee Act Database--https://www.fido.gov/facadatabase/public.asp.
    Written statements that do not pertain to the scheduled meeting of 
the Panel

[[Page 10790]]

may be submitted at any time. However, if individual comments pertain 
to a specific topic being discussed at a planned meeting, then these 
statements must be submitted no later than 5 business days prior to the 
meeting in question. The Designated Federal Officer will review all 
submitted written statements and provide copies to all the committee 
members.

Public Comments

    In addition to written statements, the Panel will set aside 1 hour 
for individuals or interested groups to address the Panel. To ensure 
consideration of their comments, individuals and interested groups 
should submit written statements as outlined in this notice; but if 
they still want to address the Panel, then they will be afforded the 
opportunity to register to address the Panel. The Panel's Designated 
Federal Officer will have a ``Sign-Up Roster'' available at the Panel 
meeting, for registration on a first-come, first-serve basis. Those 
wishing to address the Panel will be given no more than 5 minutes to 
present their comments, and at the end of the 1-hour time period no 
further public comments will be accepted. Anyone who signs up to 
address the Panel but is unable to do so due to the time limitation may 
submit their comments in writing; however, they must understand that 
their written comments may not be reviewed prior to the Panel's 
deliberation. Accordingly, the Panel recommends that individuals and 
interested groups consider submitting written statements instead of 
addressing the Panel.

Waiver

    Due to internal DoD difficulties, beyond the control of the Uniform 
Formulary Beneficiary Advisory Panel or its Designated Federal Officer, 
the Government was unable to process the Federal Register notice for 
the March 25, 2010, meeting of the Uniform Formulary Beneficiary 
Advisory Panel as required by 41 CFR 102-3.150(a). Accordingly, the 
Committee Management Officer for the Department of Defense, pursuant to 
41 CFR 102-3.150(b), waives the 15-calendar day notification 
requirement.

    Dated: March 3, 2010.
Mitchell S. Bryman,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2010-4954 Filed 3-8-10; 8:45 am]
BILLING CODE 5001-06-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>